Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

translation of the original Japanese news release was provided by AnGes.

             Announcement of Results of Phase III Clinical Trials

                         of HGF Gene Therapy in Japan

AnGes conducted an interim analysis of the PIII data using HGF Gene (AMG 0001) for Critical Limb Ischemia (CLI) in Japan, and is pleased to announce that remarkable improvement was observed in the AMG0001 group compared with the Placebo group.

Yesterday, an IDMC (Independent Data Monitoring Committee) was held, and now that the efficacy of AMG0001 is confirmed, the committee recommended to stop this trial in order to prevent potential ethical issues against the placebo group subjects. AnGes has accepted this advice today and decided to stop this trial. From now on, AnGes will closely communicate with governmental agencies and prepare for NDA filing.

Outline of Study Results

This trial is a randomized, placebo-controlled, double blind study for CLI subjects using AMG 0001.

In this efficacy evaluation, 40 subjects with CLI were evaluated. 27 subjects received AMG0001, and were compared with 13 placebo subjects. (The AMG0001 group received 8mg (4mg x 2) of AMG0001.)

The primary endpoints, which is, improvement of rest pain ((VAS (Visual Analog Scale)) or ischemic ulcer size, at 12 weeks post dosing, showed 30.8% improvement in Placebo group and 70.4% improvement in AMG0001 group and verified statistically significant difference (p=0.014)

As for safety, 41 subjects (AMG0001: 28 subjects, Placebo: 13 subjects) were evaluated.

Adverse drug reaction were equally distributed between AMG0001 group and placebo group.

There were 8 SAEs in 6 subjects in the AMG0001 group (peripheral ischemia, cerebella infarction, post procedural hematoma, prostate cancer, bladder perforation, acute renal failure, peritonitis, bacterial pneumonia). However, causality due to AMG0001 was estimated none or low. In Placebo group, th
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/22/2014)... 2014  Early symptoms of diabetic eye and ... new technology, coupled with yearly, comprehensive eye exams, ... detection of eye diseases, including those associated with ... left untreated, these diseases can potentially lead to ... Recently, optometric researchers have deployed a new tool ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
Breaking Medicine Technology:Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... 20, 2014 The newly updated Worldwide ... of thousands of facts, figures and forecasts on the ... medical sector forecast categories the Worldwide Medical Market ... and national views on the worldwide medical market to ... report gives you data for 2010-2019, covering each country ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... which claim to use subtle energy to stimulate the ... the intensity of pain in a number of conditions, ... in dementia, over and above what standard treatments can ... Jain, from the UCLA Division of Cancer Prevention and ...
... FRANCISCO, Oct. 29 VIA Pharmaceuticals, Inc. (Nasdaq: ... the development of compounds for the treatment of ... Rebecca Taub, Senior Vice President Research & Development ... Targeting Cardiometabolic Disease", and will discuss the Company,s ...
... employers to take heed , THURSDAY, Oct. 29 (HealthDay News) ... it might get worse -- at least for a while. ... report that stress levels peak when people reach their early ... age. , That,s not necessarily good news, either: Work-related ...
... ... Business Journal’s 11th annual award for the health care company category , ... Pompano Beach, FL (PRWEB) October 29, ... Health Care Award in the health care company category. The South Florida Business ...
... found that rheumatoid arthritis (RA) patients did not experience ... after starting anti-tumor necrosis factor (TNF) therapy. The ... Karolinska University Hospital in Stockholm, Sweden assessed the short-term ... therapies: infliximab, adalimumab, and etanercept. Details of the ...
... ... stereotypes , ... Arlington, VA (PRWEB) October 28, 2009 -- As Halloween approaches, the National Alliance ... costumes and other seasonal attractions that feature inaccurate and offensive stereotypes regarding those with ...
Cached Medicine News:Health News:Biofield therapies: Helpful or full of hype? 2Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 2Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 3Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 4Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 5Health News:After Age 55, Workplace Stress Seems to Decline 2Health News:American Diabetes Wholesale Wins 2009 Excellence In Health Care Award from South Florida Business Journal 2Health News:Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patients 2Health News:NAMI Issues "Stigma Alert" Over Inaccurate and Offensive Halloween Costumes, Attractions 2Health News:NAMI Issues "Stigma Alert" Over Inaccurate and Offensive Halloween Costumes, Attractions 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: